discuss
drug
drug
develop
usual
one
think
allorgan
molecul
rather
contain
metalmaingroup
element
estim
organ
drug
bioinspir
deriv
natur
product
put
metalbas
drug
normal
synthet
metalbas
drug
offer
consider
advantag
allorgan
drug
molecul
may
function
carrier
otherwis
unstabl
organ
drug
socal
trojan
hors
strategi
offer
opportun
control
releas
drug
crucial
may
fact
key
therapeut
benefit
despit
domin
organ
molecul
chemotherapi
interest
modern
chemotherapi
wide
acknowledg
begun
work
paul
ehrlich
investig
efficaci
arsen
compound
treatment
exampl
african
trypanosominasi
evid
metal
featur
promin
tradit
medicin
variou
societi
adopt
contemporari
medicin
well
develop
content
support
fact
sever
metalbas
drug
domin
role
modern
chemotherapi
perhap
notabl
among
cisplatin
secondgener
platinum
complex
use
success
treatment
variou
type
cancer
promin
element
includ
vanadium
treatment
type
diabet
gold
sever
case
rheumatoid
arthriti
directli
relev
present
chapter
arsen
treatment
specif
form
leukemia
antimoni
treatment
tropic
diseas
leishmaniasi
bismuth
peptic
duoden
ulcer
caus
helicobact
pylori
interest
specif
metal
appear
target
specif
diseas
multitud
metal
compound
continu
evalu
efficaci
full
rang
human
afflict
literatur
describ
develop
steadili
grow
comprehens
literatur
emerg
two
book
dedic
topic
metalbas
drug
appear
recent
year
complement
numer
review
recent
exampl
focus
gener
aspect
metal
complex
treatment
cancer
doubt
endeavor
attract
attent
context
tropic
diseas
diabet
enzym
inhibit
reflect
grow
interest
review
also
avail
describ
develop
organometal
compound
therapeut
agent
intriguingli
metalorgan
framework
mof
may
function
drug
carrier
new
type
drug
deliveri
system
present
chapter
brief
overview
heavier
maingroup
element
given
follow
descript
use
realiz
potenti
element
contemporari
medicin
discuss
lithium
salt
long
use
treatment
neurogen
diseas
also
includ
descript
role
maingroup
element
medicin
emphasi
place
known
biolog
target
mechan
action
rather
comprehens
survey
maingroup
element
compound
evalu
biolog
activ
emphasi
research
recent
literatur
last
year
chapter
organ
term
group
group
period
tabl
start
gallium
within
section
row
row
chapter
conclud
descript
lithium
salt
medicin
gallium
compound
receiv
signific
attent
term
therapeut
applic
particular
owe
demonstr
anticanc
activ
potenti
review
along
use
diagnost
agent
toxic
consider
less
attent
devot
indium
compound
although
promis
trial
report
therapeut
role
yet
identifi
thallium
compound
gallium
ga
histor
import
discov
frenchman
pe
lecoq
de
boisbaudran
observ
gallium
anticip
properti
ekaaluminum
exist
predict
mendeleev
year
earlier
first
mendeleev
element
uncov
discoveri
pave
way
gener
accept
period
tabl
gallium
domin
oxid
state
compound
promis
candid
anticanc
therapi
due
similar
ga
ion
fe
term
exampl
electroneg
electron
affin
ionic
radiu
coordin
geometri
redox
chemistri
ga
readili
access
biolog
media
similar
suggest
ga
ion
follow
biochem
pathway
similar
found
iron
metabol
thu
ga
known
modifi
threedimension
structur
dna
inhibit
synthesi
modul
protein
synthesi
inhibit
activ
number
enzym
atpas
dna
polymeras
ribonucleotid
reductas
tyrosinespecif
protein
phosphatas
gallium
second
metal
platinum
use
cancer
treatment
anticanc
properti
describ
first
time
gallium
nitrat
ga
ganit
approv
treatment
malignancyassoci
hypercalcemia
administ
intraven
ga
also
activ
proapoptot
gene
bax
therebi
induc
apoptosi
mitochondri
pathway
import
develop
recent
preclin
studi
show
novel
compound
tri
gallium
iii
gallium
maltol
octahedr
geometri
base
donor
set
defin
three
chelat
ligand
figur
inhibit
growth
lymphoma
cell
resist
significantli
greater
antineoplast
activ
panel
lymphoma
cell
line
therefor
develop
gallium
compound
greater
efficaci
consider
interest
attract
increas
attent
may
advanc
use
gallium
clinic
hydrolyt
stabil
abil
penetr
cell
membran
impart
gallium
coordin
complex
improv
intestin
absorpt
lead
increas
plasma
concentr
gallium
compar
gallium
nitrat
chlorid
salt
gallium
activ
tumor
thought
due
antiprolif
antimitot
effect
gallium
get
cell
exert
antiprolif
effect
inhibit
ribonucleosid
diphosph
reductas
rdr
due
competit
bind
ga
fe
gallium
affect
intracellular
iron
avail
also
interact
directli
rdr
displac
iron
enzym
tumor
cell
sensit
cytotox
effect
rdr
inhibit
normal
cell
increas
need
deoxynucleotid
triphosph
prolifer
decreas
adapt
low
respons
regulatori
signal
thu
enzym
long
consid
excel
target
cancer
chemotherapi
owe
benefit
outlin
well
due
better
antiprolif
properti
greater
bioavail
suitabl
oral
administr
two
compound
aforement
gallium
maltol
tri
gallium
iii
select
evalu
structur
featur
octahedr
geometri
mer
distribut
donor
phenoxidoo
atom
figur
compound
alreadi
finish
phase
clinic
trial
expect
enter
second
phase
even
though
antitumor
effect
gallium
compound
demonstr
sometim
ago
optimum
schedul
administr
still
need
determin
background
surpris
gallium
compound
investig
put
antitumor
activ
among
bi
gallium
iii
tetrachloridogal
iii
select
seri
gallium
compound
clinic
develop
salt
compris
cation
octahedr
coordin
gallium
atom
within
n
donor
set
defin
two
trident
ligand
sulfur
ci
figur
tetrahedr
coordin
gallium
atom
anion
compound
rapidli
bound
transferrin
fact
correl
greater
antiprolif
activ
keep
notion
organometal
compound
attract
increas
attent
potenti
therapeut
agent
number
recent
studi
describ
cytotox
assay
rang
human
cancer
cell
line
diorganogallium
iii
compound
exampl
dinuclear
complex
bi
dimethylgallium
shown
figur
featur
tetrahedr
coordin
gallium
within
c
donor
set
heterocycl
thiolat
deriv
also
display
signific
cytotox
tetranuclear
analog
organogallium
compound
appear
caus
apoptosi
via
extrins
pathway
upregul
caspas
vivo
result
yet
report
organometal
compound
bi
phenolato
gallium
iii
perchlor
exhibit
signific
antitumor
activ
mice
bear
xenograph
observ
correl
signific
inhibit
proteasom
activ
induct
apoptosi
addit
anticanc
trial
recent
studi
indic
gallium
compound
may
efficaci
novel
antimicrobi
agent
import
develop
given
tendenc
microorgan
develop
resist
current
therapi
gallium
vitro
bactericid
activ
exampl
pseudomona
aeruginosa
rhodococcu
equi
salmonella
figur
molecular
structur
bi
gallium
iii
cation
tetrahedr
gacl
anion
shown
bi
dimethylgallium
addit
color
code
sulfur
yellow
newport
staphylococcu
speci
gramneg
gramposit
bacteria
antimicrobi
effect
gallium
relat
biochem
similar
iron
ionic
radii
properti
ga
fe
ion
similar
mention
ga
substitut
fe
irondepend
biolog
process
bacteri
iron
scaveng
transport
system
well
enzym
synthesi
pathway
fact
ga
taken
preferenti
fe
bacteria
bind
ferric
site
transferrin
also
preferenti
taken
mononuclear
phagocyt
site
inflamm
howev
unlik
fe
ga
reduc
dival
form
physiolog
condit
preclud
particip
crucial
bacteri
irondepend
dna
synthet
pathway
therebi
account
gallium
antimicrobi
activ
pathogen
bacteria
depend
upon
iron
use
gallium
may
repres
new
treatment
strategi
bacteri
infect
coordin
gallium
iii
organ
ligand
could
also
improv
antimicrobi
action
gallium
increas
lipophil
bioavail
addit
use
appropri
ligand
metalligand
synerg
could
occur
thiosemicarbazon
metal
complex
present
wide
pharmacolog
versatil
applic
antitumor
antivir
antimicrobi
agent
extens
investig
recent
studi
suggest
coordin
variou
pyridinesubstitut
thiosemicarbazon
structur
relat
cation
tran
sulfur
atom
could
interest
strategi
enhanc
metal
ligand
activ
antibacteri
activ
gramneg
bacilli
p
aeruginosa
moreov
sinc
thiosemicarbazon
gener
poorli
activ
gramneg
bacteria
coordin
gallium
could
effici
strategi
broaden
spectrum
antibacteri
action
use
siderophor
desferrioxamin
carrier
gallium
also
prove
effect
strategi
combat
p
aeruginosa
gallium
iii
maltol
shown
signific
inhibitori
effect
vitro
growth
staphylococcu
aureu
methicillinresist
aureu
methicillinresist
pseudintermediu
r
equi
aureu
major
caus
surgic
site
infect
hospitalacquir
bacteremia
subsequ
lifethreaten
infect
manifest
necrot
fasciiti
pneumonia
septic
arthriti
osteomyel
endocard
indic
gallium
maltol
may
use
treatment
staphylococc
infect
veterinari
speci
infect
aureu
particularli
use
topic
local
therapi
addit
known
antitumor
activ
necessarili
therapeut
agent
complet
reflect
evergrow
interest
gallium
therapeut
applic
worth
mention
incorpor
gallium
phosphat
glass
slow
releas
ga
convers
report
recent
bioceram
gel
incorpor
ga
may
employ
slow
releas
bioactiv
molecul
curcumin
yellow
antibacteri
pigment
major
compon
turmer
rel
rare
element
indium
consid
nontox
sourc
rel
recent
research
potenti
medic
radiodiagnost
applic
indium
compound
emerg
literatur
gener
phobia
heavier
element
might
partli
respons
inact
like
ga
known
interact
transferrin
ironbind
blood
plasma
glycoprotein
control
level
free
iron
biolog
fluid
therebi
provid
like
mechan
transport
across
cell
membran
inlabel
compound
administ
weakli
bound
ligand
acid
solut
found
bind
protein
mainli
transferrin
crucial
transferrin
protein
load
iron
encount
transferrin
receptor
tfr
surfac
cell
bind
transport
cell
vesicl
receptormedi
endocytosi
suggest
indiumload
transferrin
similarli
transport
although
transferrin
bind
tfr
well
diferr
transferrin
transport
across
cell
membran
much
slower
case
ga
howev
still
tend
accumul
tissu
high
level
tfr
seem
like
transferrin
mediat
deliveri
tumor
case
clear
indium
iii
compound
use
first
step
classic
iron
pathway
reach
blood
stream
may
import
consequ
relat
toxicolog
radiopharmaceut
role
compound
term
biolog
screen
report
rare
trial
involv
indium
iii
metal
varieti
human
cell
line
compound
prove
cytotox
cancer
cell
line
investig
also
normal
cell
line
notabl
except
tri
indium
iii
like
mer
distribut
nitrogen
atom
tri
gallium
iii
compound
lower
cytotox
murin
hepatoma
tumor
cell
compar
metal
complex
evalu
exampl
rhodium
osmium
iridium
antimoni
bismuth
consider
lower
cytotox
time
normal
nih
fibroblast
indic
select
inhibitori
activ
mycobacterium
tuberculosi
select
metal
ion
coadminist
macrocycl
compound
includ
acid
prove
efficaci
indium
iii
equimolar
concentr
free
cation
v
fe
bi
test
vitro
tuberculosi
metal
compound
exhibit
greater
activ
uncoordin
macrocycl
radiometr
inhibit
rang
compound
vanadium
iv
bismuth
iii
indium
iii
order
increas
activ
highest
radiometr
inhibit
level
obtain
compound
caus
drop
log
unit
cellular
viabil
mention
curcumin
natur
antibacteri
agent
indium
iii
compound
display
enhanc
activ
compar
varieti
bacteria
includ
aureu
escherichia
coli
two
bacteria
also
featur
separ
trial
indium
iii
compound
neutral
schiff
base
molecul
contain
adamantan
residu
exampl
trigon
bipyramid
tran
oxygen
atom
figur
evalu
case
indium
iii
compound
prove
activ
uncoordin
schiff
base
molecul
prove
import
metal
particularli
higher
concentr
final
complet
sever
recent
studi
report
efficaci
indium
iii
phthalocyanin
compound
includ
watersolubl
cation
deriv
use
photodynam
therapi
pdt
exampl
treatment
cancer
aforement
evalu
indium
iii
compound
biolog
activ
clearli
infanc
given
initi
promis
result
addit
studi
clearli
warrant
maingroup
element
compound
cover
chapter
tin
iv
compound
particular
organotin
iv
compound
attract
attent
especi
put
antitumor
potenti
despit
effort
potenti
remain
larg
unreal
biolog
activ
exampl
antimicrobi
antivir
antifung
also
attract
consider
attent
contrast
potenti
efficaci
germanium
iv
compound
receiv
much
less
attent
even
though
specif
deriv
undergon
clinic
evalu
evalu
signific
toxic
found
see
surprisingli
owe
known
toxic
limit
number
studi
appear
potenti
lead
compound
therapeut
agent
germanium
ge
metalloid
known
semiconduct
properti
owe
low
natur
abund
germanium
discov
rel
recent
gallium
interestingli
gallium
mendeleev
predict
exist
name
ekasilicon
germanium
iv
either
molecular
compound
inorgan
form
may
modul
immun
respons
reduc
mutagen
genotox
toxic
even
possess
antimicrobi
activ
although
report
reveal
clinic
effect
germanium
iv
compound
cellular
molecular
respons
molecul
well
understood
studi
requir
explor
biolog
impact
germanium
iv
compound
consider
demonstr
biolog
activ
sever
dnadamag
agent
arrest
transit
mphase
cell
cycl
delay
phase
hypothes
enabl
repair
damag
dna
cyclindepend
kinas
cdk
key
regul
mammalian
cell
cycl
regul
occur
cyclin
product
destruct
reloc
inhibitori
activ
phosphoryl
event
kinas
activ
critic
cellcycl
progress
mitosi
recogn
valid
anticanc
target
report
inhibitor
effect
arrest
tumor
cell
growth
prompt
recent
interest
discoveri
develop
new
inhibitor
germanium
oxid
geo
found
block
cellcycl
progress
phase
chines
hamster
ovari
cell
surprisingli
delay
due
dna
damag
due
reduct
activ
geo
treatment
despit
encourag
result
attent
direct
toward
evalu
anticanc
potenti
molecular
germanium
iv
compound
promin
organogermanium
iv
compound
found
exhibit
signific
antiprolif
activ
human
tumor
includ
bi
sesquioxid
also
known
organ
germanium
n
dihydrochlorid
commonli
known
spirogermanium
inhibit
growth
divers
fluid
solid
tumor
toxic
appear
major
issu
use
wide
dietari
supplement
earli
clinic
studi
display
activ
advanc
ovarian
carcinoma
lymphocyt
lymphoma
compound
report
enhanc
sever
cytokin
interferongamma
infg
may
due
antioxid
effect
compound
facilit
oxygen
entri
primari
electron
acceptor
red
blood
cell
cancer
cell
util
oxygen
actual
appear
oxygen
sensit
presenc
oxygen
catalyst
could
deleteri
effect
like
therapeut
valu
exact
anticanc
mechan
compound
remain
unclear
howev
recent
studi
evalu
cytotox
hydroxyl
deriv
suggest
may
possess
dnabind
specif
like
cisplatin
inhibit
cancer
cell
prolifer
next
group
biolog
activ
organogermanium
compound
attract
consider
attent
germatran
see
archetyp
structur
germatran
tetracoordin
contain
hyperval
germanium
owe
format
transannular
bond
nitrogen
featur
impart
chemic
stabil
molecul
natur
r
substitu
germanium
atom
influenc
strength
n
ge
bond
biolog
properti
biolog
investig
demonstr
certain
bromobenzylgermatran
low
toxic
ld
mg
kg
high
anesthet
anticorazol
activ
may
improv
memori
process
complet
prevent
anim
retrograd
amnesia
caus
electroshock
beyond
studi
investig
biolog
activ
compar
rare
sporad
recent
studi
compound
demonstr
enhanc
protoporphyrin
ix
therefor
point
possibl
role
treatment
chronic
hepat
trimethylgermanium
iv
sugar
deriv
origin
synthes
desir
reduc
contamin
inorgan
germanium
drug
formul
trial
show
effect
induc
infg
concomit
enhanc
antiprolif
activ
final
complex
diorganogermanium
iv
schiff
base
deriv
exampl
trigon
bipyramid
screen
antifung
antibacteri
activ
show
germaniumcontain
compound
effect
uncoordin
ligand
effect
standard
antimicrobi
agent
tin
sn
compound
often
organotin
iv
compound
arguabl
among
maingroup
element
survey
herein
attract
greatest
attent
term
attempt
drug
discoveri
particular
potenti
antitumor
agent
reason
attent
vari
howev
fair
state
one
two
notabl
except
attent
receiv
compound
result
signific
breakthrough
term
new
drug
also
disappoint
lack
knowledg
possibl
biolog
mechan
could
drive
ration
drug
discoveri
abil
inhibit
cancer
cell
organotin
known
year
much
tremend
impetu
studi
organotin
compound
rest
high
vitro
cytotox
exhibit
compar
cisplatin
benchmark
metalbas
anticanc
drug
especi
use
treat
testicular
ovarian
bladder
headneck
cancer
sever
comprehens
review
potenti
antitumor
activ
tin
compound
appear
recent
year
uniformli
highlight
divers
rang
organ
molecul
coordin
tin
center
normal
organotin
compound
includ
review
organotin
deriv
coordin
molecul
function
drug
right
even
identif
definit
structur
relationship
mechan
action
still
want
tin
iv
hard
metal
center
surpris
tin
compound
prefer
bind
phosphateoxygen
polyanion
structur
dna
forc
conform
chang
tin
compound
also
known
act
strong
apoptot
director
activ
apoptosi
directli
via
tumor
suppressor
pathway
tnfrelat
apoptosisinduc
ligand
trail
receptor
caspas
famili
protein
sinc
two
primari
mode
apoptosi
metalinduc
apoptosi
thought
initi
intracellularli
mitochondria
pertin
mediat
apoptosi
via
metalinduc
reactiv
oxygen
speci
ro
follow
brief
summari
studi
given
potenti
activ
coupl
investig
possibl
mechan
action
earli
vitro
studi
dinbutyltin
dichlorid
trinbutyltin
chlorid
show
induc
apoptosi
rat
thymocyt
inhibit
dna
synthesi
increas
rna
synthesi
apoptot
pathway
induc
commenc
increas
concentr
ca
ion
follow
releas
mitochondri
cytochrom
c
activ
caspas
final
result
dna
fragment
recent
studi
avail
organotin
compound
carri
organ
ligand
compound
attract
earli
attent
triethyltin
iv
lupinylsulfid
hydrochlorid
quinolizidin
deriv
develop
potenti
antitumor
agent
compound
exhibit
potent
antiprolif
effect
differ
human
cancer
cell
line
appear
dna
primari
target
rather
perturb
homeostasi
impair
mitochondri
function
inhibit
protein
synthesi
may
primarili
respons
cytotox
n
hcl
snet
triphenyltin
iv
compound
diphenyltin
iv
bi
thiolat
skewtrapezoid
bipyramid
coordin
geometri
phenyl
ring
lie
weaker
snn
bond
figur
display
interest
correl
cytotox
inhibit
lipoxygenaseinduc
peroxid
linol
acid
organotin
carboxyl
receiv
signific
attent
term
abil
exhibit
promis
cytotox
profil
seri
tricyclohexyltin
carboxyl
exemplifi
pentacoordin
tin
compound
featur
asymmetr
coordin
carboxyl
ligand
cell
line
known
express
pglycoprotein
studi
compound
shown
substrat
protein
efflux
pump
key
indic
compound
induc
multidrug
resist
mention
vivo
studi
compar
rare
tin
compound
howev
recent
report
emerg
vivo
studi
carri
dinbutylchloridotin
iv
illustr
figur
exhibit
trigon
bipyramid
geometri
one
oxygen
chlorid
atom
axial
posit
compound
shown
display
good
doseeffect
relationship
liver
tumor
sarcoma
close
exhibit
cisplatin
well
dose
depend
mice
ehrlich
ascit
tumor
recent
studi
anoth
seri
diorganotin
compound
found
caus
apoptot
death
via
differ
pathway
particular
one
antiprolif
antitumor
activ
dinbutyldichloridotin
iv
phenyliminomethyl
pyridin
featur
octahedr
c
cl
n
coordin
geometri
figur
shown
significantli
block
cellcycl
progress
induc
chromosom
aberr
sister
chromatid
exchang
human
lymphocyt
rais
level
protein
antitumor
potenti
explor
dinuclear
compound
featur
two
triphenyltin
iv
residu
connect
bridg
dianion
one
via
chelat
n
group
give
rise
trigon
bipyramid
tin
center
chelat
oxygen
atom
asymmetr
coordin
carboxyl
group
distort
octahedr
coordin
geometri
complet
oxygen
atom
solvent
aceton
molecul
figur
studi
report
cytotox
effect
exert
might
part
due
apoptosi
leiomyosarcoma
human
breast
adenocarcinoma
cell
line
apoptot
death
caus
also
confirm
dna
fragment
analysi
typic
pattern
oligonucleosomals
fragment
also
observ
mean
surviv
time
observ
wistar
rat
inocul
accompani
reduc
cancer
volum
complet
cure
anim
rather
oper
potenti
drug
treatment
cancer
tin
iv
porphyrin
compound
commonli
known
tin
ethyl
etiopurpurin
employ
photosensit
agent
pdt
clinic
trial
shown
efficaci
treatment
cutan
basal
cell
cancer
breast
metastasi
chest
wall
kaposi
sarcoma
photosensit
demonstr
great
promis
produc
excel
preliminari
clinic
result
brought
commerci
realiz
thu
far
focu
section
upon
cancer
tin
compound
also
evalu
activ
diseas
organotin
iv
compound
attract
attent
also
wide
varieti
biolog
activ
includ
bactericid
acaricid
fungicid
aspect
review
recent
mechanist
studi
still
rare
recent
studi
except
regard
sever
organotin
compound
includ
dinbutyltin
iv
bi
aminobenzo
skewtrapezoid
bipyramid
geometri
tinbound
organ
group
lie
weaker
sno
bond
figur
evalu
candida
albican
chang
dna
integr
mitochondria
function
observ
howev
organotin
compound
survey
found
reduc
ergosterol
biosynthesi
caus
sever
damag
c
albican
cell
compromis
cellular
integr
suggest
organotin
complex
act
cell
membran
view
cytoplasm
leak
cellular
deform
studi
also
indic
mechan
action
organotin
compound
similar
azol
drug
ketoconazol
fluconazol
normal
use
candida
infect
recent
studi
describ
antiinflammatori
activ
organotin
iv
tryptophanylglycin
exemplifi
dinbutyltin
iv
tryptophanylglycin
exhibit
first
approxim
trigon
bipyramid
geometri
carboxylateo
aminen
atom
defin
axial
posit
figur
coordin
geometri
rather
larg
void
csnc
angl
approxim
occupi
two
carboxylateo
atom
sno
anoth
molecul
lead
supramolecular
chain
henc
tin
atom
coordin
geometri
base
cpentagon
bipyramid
biolog
screen
compound
indic
good
antiinflammatori
activ
limit
side
effect
cardiovascular
systemblood
pressur
final
antileishmani
activ
demonstr
organotin
compound
exhibit
dinbutyltin
iv
formylhydrazin
least
studi
element
group
compound
lead
pb
wellknown
toxic
also
see
chapter
leadlead
compound
undoubtedli
limit
interest
explor
potenti
therapeut
thu
except
result
crous
group
investig
lead
ii
heavi
element
dithiocarbaz
virtual
recent
studi
report
lead
ii
complex
monoanion
deriv
product
highli
cytotox
leukem
cell
cemss
ic
mg
cm
wherea
pbno
salt
inact
condit
anoth
studi
lead
ii
coordin
dithiocarbaz
deriv
product
display
mark
cytotox
human
myeloid
leukemia
ic
downplay
real
difficulti
associ
toxic
element
lead
possibl
drug
may
emerg
therapeut
window
identifi
allow
benefici
dose
administ
idea
better
illustr
next
section
therapeut
use
arsen
outlin
contrast
element
belong
group
cover
survey
member
group
play
promin
role
contemporari
medicin
arsen
antimoni
bismuth
compound
clinic
applic
cancer
leishmaniasi
stomach
ulcer
respect
detail
element
evalu
rang
biolog
efficaci
brief
mention
also
made
arsen
compound
use
medicin
year
ailment
ulcer
plagu
malaria
target
arsen
formul
period
inde
arsen
play
import
role
develop
modern
chemotherapi
key
compon
paul
ehrlich
magic
bullet
salvarsan
known
prodrug
releas
therapeut
activ
speci
arson
acid
mani
compound
prepar
time
salvarsan
develop
erad
treponema
pallidum
caus
bacterium
syphili
inde
use
continu
supplant
penicillin
arsen
compound
also
long
known
exhibit
anticanc
activ
summar
recent
bibliograph
review
fowler
solut
compris
potassium
arsenit
kaso
better
known
rodenticid
report
activ
leukemia
use
clinic
continu
middl
twentieth
centuri
replac
busulfan
dimethanesulfon
mention
arsen
compound
either
alon
combin
drug
use
treatment
rang
diseas
includ
syphili
psoriasi
trypanosomiasi
human
african
sleep
sick
pernici
anemia
hodgkin
diseas
clinic
util
arsen
compound
subsequ
evalu
anticanc
potenti
promin
among
trypanocid
melarsoprol
amebicid
bactericid
arsthinol
exhibit
antitumor
potenti
far
greatest
attent
devot
arsen
trioxid
distribut
trisenox
recent
use
primari
drug
combat
chronic
myeloid
leukemia
well
leukemia
gall
bladder
esophag
prostat
ovarian
carcinoma
current
research
indic
chemotherapeut
effect
aris
due
abil
modul
sever
pathway
cancer
cell
attribut
lead
increas
apoptosi
enhanc
differenti
inhibit
cell
prolifer
angiogenesi
also
known
target
mitochondria
cancer
cell
line
result
decreas
mitochondri
membran
potenti
induct
ro
releas
cytochrom
c
activ
sever
cell
death
pathway
also
known
interact
gene
patient
suffer
apl
tend
overexpress
pmlrara
fusion
gene
result
transloc
chromosom
therefor
import
induc
inactiv
degrad
pmlrara
gene
known
inhibit
express
gene
associ
myeloid
differenti
literatur
report
indic
also
decreas
express
gene
involv
angiogenesi
vascular
endotheli
growth
factor
vegf
cell
prolifer
cyclin
surviv
nfkb
cancer
cell
line
noteworthi
current
use
anticanc
drug
curcumin
betulin
acid
tolfenam
acid
function
similarli
decreas
express
gene
effect
ascrib
decreas
express
specif
protein
transcript
factor
sp
overexpress
mani
tumor
known
bind
guaninecytosinerich
promot
element
sp
regul
gene
express
gene
vegf
cyclin
nfkb
also
decreas
cancer
cell
transfect
mixtur
isp
small
inhibitori
rna
abil
interact
gene
implic
patient
suffer
gall
bladder
carcinoma
report
inhibit
prolifer
gall
bladder
carcinoma
vitro
vivo
well
transcript
cellcyclerel
protein
cyclin
overexpress
cyclin
inhibit
neg
role
cellcycl
progress
furthermor
transcript
factor
downregul
correspond
decreas
cyclin
promot
activ
taken
togeth
result
suggest
inhibit
gall
bladder
carcinoma
cell
prolifer
via
downregul
cyclin
transcript
manner
provid
new
mechan
cell
prolifer
may
import
therapeut
implic
gall
bladder
carcinoma
patient
singleag
activ
myeloma
singleag
mg
kg
day
day
phase
ii
trial
multipl
myeloma
patient
advanc
extens
pretreat
refractori
diseas
patient
achiev
partial
respons
addit
preclin
evid
synergist
interact
doxorubicin
shown
increas
intracellular
accumul
doxorubicin
hepatocellular
carcinoma
recent
studi
shown
agent
paclitaxel
ptx
combin
treatment
low
concentr
could
synergist
inhibit
prolifer
decreas
cell
viabil
lymphocyt
leukemia
cell
enhanc
mitot
arrest
activ
spindl
checkpoint
suggest
clinic
trial
combin
regimen
ptx
deserv
perform
refractori
patient
acut
lymphoblast
leukemia
final
recent
research
reveal
treatment
reduc
express
transcript
level
tumor
cell
respons
initi
propag
recurr
tumor
highli
resist
convent
chemotherapi
effect
induc
gall
bladder
carcinoma
cell
apoptosi
furthermor
ectop
express
attenu
apoptot
effect
cell
activ
akt
protein
kinas
b
signal
pathway
summari
effect
target
gall
bladder
carcinoma
provid
new
mechan
cell
apoptosi
better
understand
drug
resist
gall
bladder
carcinoma
despit
fact
antimoni
sb
compound
forefront
treatment
leishmaniasi
mani
decad
explor
therapeut
use
antimoni
attract
signific
interest
may
real
anticip
toxic
side
effect
associ
antimoni
compound
indic
discuss
therapeut
arsen
necessarili
mitig
therapeut
applic
antimoni
v
contain
compound
sodium
stiboglucon
pentostam
meglumin
antimonit
well
antimoni
iii
compound
sodium
antimoni
iii
glucon
triostam
potassium
antimoni
iii
tartrat
tartar
emet
wide
use
treatment
leishmaniasi
leishmaniasi
diseas
temper
tropic
countri
manifest
skin
lesion
cutan
mucocutan
leishmaniasi
anoth
form
viscer
leishmaniasi
may
affect
vital
organ
fatal
diseas
spread
bite
specif
speci
sandfli
infect
host
parasit
use
antimoni
compound
treatment
leishmaniasi
notwithstand
mechan
action
antimoni
drug
yet
complet
understood
situat
made
easier
fact
precis
chemic
structur
drug
known
chemic
structur
shown
repres
chemic
composit
propos
antileishmani
activ
antimoni
v
compound
depend
reduct
antimoni
iii
insid
parasit
tripeptid
glutathion
gsh
glglulcysgli
trypanothion
sh
conjug
glutathion
polyamin
spermin
n
n
bi
glutathionyl
spermidin
henc
antimoni
v
drug
consid
less
toxic
prodrug
toxic
antimoni
iii
compound
display
antileishmani
activ
owe
abil
antimoni
coordin
trypanothion
reductas
tr
enzym
respons
variou
trypanosom
protect
free
radic
therefor
essenti
surviv
parasit
virul
recent
studi
indic
combin
suboptim
dose
diperoxovanad
compound
k
vo
h
may
benefici
treatment
viscer
leishmaniasi
patient
signific
reduct
organ
parasit
burden
combin
highli
effect
combat
experiment
infect
balbc
mice
leishmania
donovani
known
antimoni
resist
also
interest
treatment
allow
clonal
express
antileishmani
tcell
togeth
robust
surg
ifng
concomit
decreas
product
splenocyt
treat
anim
gener
significantli
higher
amount
ifnginduc
parasiticid
effector
molecul
superoxid
nitric
oxid
compar
infect
group
keep
abil
antimoni
iii
interact
tr
see
fact
tr
also
occur
trypanosoma
suggest
tr
might
promis
target
develop
trypanocid
drug
treatment
sleep
sick
chaga
diseas
therebi
open
anoth
opportun
antimoni
iii
compound
accordingli
investig
antitrypanosom
activ
antimoni
iii
thiosemicarbazon
compound
carri
exemplifi
dichloridoantimoni
iii
figur
immedi
environ
antimoni
iii
atom
compris
n
donor
atom
unineg
trident
ligand
two
chlorid
atom
defin
highli
distort
trigon
bipyramid
coordin
geometri
supramolecular
associ
via
interact
led
polymer
chain
distort
octahedr
coordin
geometri
figur
base
mercl
n
donor
set
vitro
trial
reveal
excel
inhibit
action
trypanosoma
cruzi
growth
antitrypanosom
mechan
action
antimoni
iii
thiosemicarbazon
compound
could
due
synergist
effect
involv
antimoni
iii
ligand
molecul
latter
also
activ
right
thought
provid
addit
function
carrier
antimoni
iii
cell
although
major
clinic
use
antimoni
compound
treatment
leishmaniasi
antitumor
potenti
antimoni
compound
report
sever
studi
particular
antimoni
iii
compound
propos
novel
therapi
apl
discuss
term
therapeut
arsen
compound
earli
studi
effect
antimoni
iii
drug
glutathion
homeostasi
oxid
stress
apoptosi
human
acut
monocyt
leukemia
cell
line
monocyt
cell
investig
shown
treat
antimoni
iii
macrophag
cell
exhibit
high
level
ro
show
earli
sign
apoptosi
studi
show
antimoni
trioxid
sb
induc
growth
inhibit
patientderiv
apl
cell
line
demonstr
treatment
inhibit
growth
sever
malign
cell
line
includ
deriv
hematolog
malign
solid
tumor
malign
cell
test
growth
inhibit
due
increas
apoptosi
well
caspas
activ
although
apl
cell
also
induc
signific
amount
granulocyt
differenti
treat
signal
pathway
apl
cell
associ
increas
apoptosi
well
differenti
marker
sb
induc
ro
correl
increas
apoptosi
addit
induc
cjun
kinas
jnk
activ
apl
cell
fibroblast
intact
bismuth
bi
compound
play
promin
role
chemotherapi
year
earli
report
document
use
bismuth
formul
treatment
gastrointestin
disord
today
bismuth
therapi
extens
use
duoden
peptic
ulcer
peptic
ulcer
may
treat
administr
colloid
bismuth
subcitr
along
bismuth
subsalicyl
use
prevent
treatment
gastric
duoden
ulcer
recent
develop
compound
ranitidin
bismuth
citrat
tritec
also
avail
treatment
antimonybas
drug
employ
treatment
leishmaniasi
precis
chemic
structur
bismuthbas
drug
larg
unknown
chemic
structur
shown
far
conclus
imag
shown
figur
repres
suppos
core
two
bismuth
iii
center
link
two
pentadent
citrat
anion
unit
connect
neighbor
build
block
gener
oligomer
aggreg
ranitidin
molecul
accommod
within
channel
defin
threedimension
framework
repres
function
exampl
use
mof
drug
carrier
lack
precis
structur
inform
common
antimoni
bismuth
drug
contrast
situat
antimoni
significantli
known
biolog
target
therapeut
bismuth
mechan
action
effect
bismuth
attribut
bactericid
action
gramneg
bacterium
h
pylori
bacterium
associ
mucu
layer
ulcer
bismuth
known
engag
exchang
reaction
thiol
therebi
inactiv
membranebound
enzym
involv
respir
h
pylori
antimicrobi
activ
bismuth
compound
toward
gramneg
bacteria
report
depend
ironuptak
system
iron
essenti
growth
h
pylori
effici
iron
acquisit
thought
import
virul
factor
bacterium
bismuth
primarili
present
red
blood
cell
possibl
bind
glutathion
remaind
serum
plasma
recent
demonstr
bind
bismuth
iii
transferrin
htf
much
stronger
human
albumin
blood
plasma
bi
associ
transferrin
presenc
larg
excess
albumin
suggest
transferrin
major
target
bismuth
iii
blood
plasma
lactoferrin
hlf
anoth
major
ironbind
protein
transferrin
famili
present
signific
amount
stomach
secret
patient
gastriti
bismuth
iii
bind
human
lactoferrin
two
ironspecif
site
presenc
either
carbon
oxal
presenc
atp
facilit
releas
bismuth
iii
lactoferrin
complex
bi
hlf
complex
block
iron
uptak
intestin
cell
consequ
bismuth
iii
may
releas
insid
cell
inhibit
target
enzym
includ
enzym
essenti
surviv
bacteria
furthermor
bi
inhibit
biolog
activ
glycin
extend
ggli
gastrointestin
hormon
biolog
activ
associ
bind
highaffin
fe
ion
bismuth
iii
inhibit
action
gastrin
block
effect
cell
prolifer
cell
migrat
gastrointestin
tract
gastrin
gastrointestin
peptid
hormon
origin
identifi
stimul
acid
secret
proteolyt
process
secretori
vesicl
antral
g
cell
gener
number
intermedi
nonamid
progastrinderiv
peptid
includ
ggli
remov
ctermin
glycin
amid
penultim
phenylalanin
yield
amid
gastrin
gamid
gamid
act
receptor
major
hormon
regul
gastric
acid
secret
mitogen
normal
gastric
epithelium
gastric
cancer
vitro
vivo
contrast
progastrin
ggli
littl
direct
effect
gastric
acid
potenti
effect
gamid
acid
secret
major
physiolog
role
progastrin
ggli
colon
progastrin
ggli
stimul
prolifer
colon
cell
line
vitro
normal
mucosa
vivo
nonamid
gastrin
may
also
act
growth
factor
colorect
cancer
bismuth
compound
demonstr
extrem
effect
inhibitor
nonamid
gastrin
abl
complet
revers
stimulatori
effect
ggli
progastrin
anim
model
suggest
bismuth
select
inhibit
prolif
effect
nonamid
gastrin
normal
colorect
mucosa
rat
mice
togeth
safe
dose
antioxid
mucos
heal
qualiti
bismuth
good
candid
allround
gastrointestin
protect
agent
concern
potenti
therapeut
applic
variou
research
group
shown
bismuth
compound
display
potent
activ
wide
rang
pathogen
includ
e
coli
legionella
pneumophila
klebsiella
pneumonia
clostridium
difficil
pseudomona
aeruginosa
aureu
includ
multiresist
strain
epidermidi
includ
methicillinresist
strain
protozoa
respons
leishmaniasi
howev
mode
action
bismuth
agent
known
perhap
interfer
iron
transport
therebi
starv
pathogen
need
iron
cellular
energyproduc
enzymat
redox
transform
also
bind
thiolcontain
bacteri
enzym
necessari
mainten
organ
within
host
recent
report
highlight
abil
bismuth
compound
includ
ranitidin
bismuth
citrat
inhibit
sar
coronaviru
strong
inhibit
atpas
activ
sar
coronaviru
helicas
protein
character
also
shown
inhibit
dna
duplex
unwind
helicas
specif
cystein
residu
report
intracellular
target
bismuth
screen
potenti
anticanc
activ
bismuth
compound
recent
review
result
focu
upon
vitro
cytotox
result
vivo
studi
demonstr
bismuth
thiolat
bismuth
iii
tri
diethyldithiocarbam
figur
antitumor
activ
compound
selfassoci
dimer
aggreg
solid
state
via
interact
coordin
geometri
base
pentagon
bipyramid
void
thought
accommod
stereochem
activ
lone
pair
electron
trial
mice
inocul
ovarian
cancer
cell
line
colon
carcinoma
cell
line
tumor
growth
arrest
former
slow
latter
element
cover
present
chapter
selenium
known
bioessenti
complement
selenium
supplement
maintain
good
health
topic
cover
herein
number
therapeut
applic
selenium
emerg
tellurium
compound
also
attract
interest
context
earli
experi
explor
antimicrobi
activ
describ
sir
alexand
fleme
selenium
se
essenti
micronutri
import
variou
aspect
human
health
includ
proper
thyroid
hormon
metabol
cardiovascular
health
prevent
neurodegener
cancer
optim
immun
respons
selenocystein
amino
acid
usual
form
selenium
found
selenoprotein
element
cover
chapter
effect
selenium
compound
supplement
chemotherapeut
agent
attract
signific
attent
cancer
treatment
first
human
intervent
trial
use
sodium
selenit
na
seo
dietari
supplement
prevent
cancer
perform
china
subject
receiv
tabl
salt
contain
subject
receiv
mg
selenium
per
day
year
incid
primari
liver
cancer
significantli
reduc
thought
induc
apoptosi
gener
ro
mitochondrialdepend
pathway
base
studi
cell
death
cervic
carcinoma
cell
h
exposur
hela
cell
line
compound
produc
timeand
dosedepend
suppress
dna
synthesi
induc
dna
damag
result
phosphoryl
histon
subsequ
activ
pathway
evidenc
appear
phosphoryl
accumul
treat
cell
concurr
activ
pathway
signal
led
accumul
protein
respons
gener
bax
proapoptot
gene
appear
mitochondria
cell
dynam
chang
initi
caspaseindepend
apoptosi
confirm
assay
activ
conclud
induc
caspaseindepend
apoptosi
cervic
carcinoma
cell
mostli
rosmedi
activ
pathway
selenitemedi
effect
particular
mitochondriaspecif
cell
also
involv
versatil
selenium
evidenc
fact
amino
acid
analog
also
display
protect
action
cancer
exampl
report
selenomethionin
vshape
geometri
selenium
atom
figur
may
protect
cancer
activ
tumor
suppressor
protein
human
lung
cancer
cell
transform
oxid
reduc
form
methyl
seleniummodifi
amino
acid
selenobetain
semethylselenocystein
action
cystein
conjug
blyas
relat
lyas
function
prodrug
releas
methylselenol
methylselenen
acid
chemoprevent
effect
low
concentr
transform
cell
vitro
way
speci
serv
reservoir
monomethyl
selenium
compound
maintain
suffici
concentr
inhibit
cell
growth
also
known
lead
signific
reduct
angiogenesi
detect
intratumor
microvessel
densiti
vegf
mammari
carcinoma
background
mind
surpris
synthet
selenium
compound
often
organoselenium
compound
evalu
anticanc
potenti
se
upon
administr
anthracen
dmba
induc
mammari
rat
tumor
immunosuppressor
dmba
power
laboratori
carcinogen
function
make
mutat
dna
methylen
selenocyan
dinuclear
molecul
bent
geometri
selenium
center
figur
suppress
format
dmbadna
adduct
dose
mg
kg
chemoprevent
activ
may
explain
part
inhibit
dna
adduct
format
inhibit
format
methylguanin
guanin
lung
mg
kg
effect
lung
tumor
induct
compliment
indic
selenium
compound
use
coadminist
drug
combin
chemotherapeut
agent
selenium
compound
may
also
provid
protect
toxic
side
effect
exampl
coadminist
sever
chemotherapeut
agent
irinotecan
fluorouracil
oxaliplatin
cisplatin
taxol
doxorubicin
maximum
toler
dose
rais
arguabl
one
promin
seleniumcontain
compound
attract
signific
attent
therapeut
potenti
ebselen
illustr
figur
individu
molecul
assembl
supramolecular
chain
solid
state
via
hyperval
interact
presenc
glutathion
peroxidas
antioxid
stimul
signific
addit
research
synthet
selenium
analog
capabl
inactiv
ro
speci
hydroperoxid
peroxynitrit
led
discoveri
subsequ
work
motiv
propos
catalyt
cycl
figur
compound
catalyz
inactiv
ro
use
varieti
thiol
substrat
includ
glutathion
reaction
thiol
cosubstr
give
ringopen
product
owe
break
sen
bond
disproportion
diselenid
ratedetermin
step
follow
reaction
h
produc
seleniumcontain
acid
either
selenen
acid
selenin
acid
form
react
thiol
give
follow
dehydrogen
regener
complet
catalyt
cycl
structureact
studi
suggest
three
key
factor
import
efficaci
name
presenc
sec
aromat
bond
suffici
stabl
prevent
releas
selenium
presenc
sen
bond
ensur
activ
akin
exhibit
glutathion
peroxidas
presenc
ndc
moieti
provid
coordin
donor
stabil
variou
intermedi
catalyt
cycl
background
antioxid
potenti
selenium
compound
surpris
consider
effort
devot
discov
synthet
seleniumbas
compound
may
function
antiinflammatori
agent
particular
given
insolubl
diselenyl
compound
mention
demonstr
abil
disrupt
normal
function
abil
inhibit
redox
activ
transcript
factor
nfkn
hope
combin
prevent
action
selenium
inhibit
abil
gener
enhanc
therapeut
benefit
led
selenium
deriv
cf
group
substitut
methyleneselanylcarbonitril
residu
compound
inhibit
macrophag
diminish
protein
express
suppress
activ
nfkn
amino
acid
selenocystein
also
found
catalyt
site
iodothyronin
deiodinas
lactoperoxidas
enzym
associ
normal
function
thyroid
gland
key
role
selenium
facilit
deiodin
thyroxin
mechan
yet
determin
known
deiodin
selenenyl
iodid
intermedi
form
react
thiol
cofactor
selenium
compound
analog
sulfur
drug
methimazol
effect
inhibit
lactoperoxidasecatalyz
reaction
relat
oxid
mechan
like
involv
reduct
h
iodin
chemic
reason
propos
account
differ
sulfur
selenium
antithyroid
drug
name
base
greater
nucleophil
selenium
sulfur
analog
exist
primarili
thion
greater
nucleophil
selenium
see
signific
contribut
zwitterion
overal
electron
structur
thu
readili
oxid
diselenid
import
inhibit
thyroid
hormon
synthesi
true
sulfur
drug
vivo
glutathion
thiol
reduc
diselenid
form
charg
highli
reactiv
speci
se
nh
nh
n
n
se
selenium
compound
includ
evalu
antimicrobi
potenti
indic
selenium
compound
effect
gramposit
strain
oppos
gramneg
strain
notabl
recent
studi
describ
effect
antistaphylococc
activ
selenium
analog
contain
drug
known
topoisomeras
poison
presenc
selenium
noncytotox
molecul
gave
rise
potent
antistaphylococc
speci
lowest
potenti
express
herg
gene
gene
code
potassium
ion
channel
protein
studi
point
potenti
efficaci
selenium
therapeut
medicin
diseas
target
recent
studi
brief
overview
given
selenium
present
molecul
diselenid
ethylcarbamoyl
phenyl
diselanyl
benzamid
gave
rise
compound
effect
antivir
agent
effect
human
herp
viru
type
encephalomyocard
viru
compar
sulfur
analog
anoth
diselenid
diselanyl
anilin
potent
seri
selenocyan
diselenid
explor
new
therapi
treatment
leishmaniasi
figur
propos
catalyt
cycl
show
abil
inactiv
h
compound
selenen
acid
selenin
acid
thiol
cycl
necessarili
glutathion
may
anoth
thiol
compound
display
potenc
promastigot
leishmania
infantum
found
sandfli
host
well
model
amastigot
found
infect
human
anoth
parasit
name
plasmodium
falciparum
target
trial
new
antimalari
compound
n
phenylselanyl
propyl
butanamid
featur
redoxmodul
quinon
residu
effect
unlik
selenium
known
natur
biolog
function
tellurium
te
also
unlik
selenium
tellurium
rel
long
histori
term
biolog
evalu
tellurium
form
potassium
tellurit
teo
attract
earli
attent
antibiot
sir
alexand
fleme
establish
activ
penicillininsensit
bacteria
contrast
penicillin
activ
telluriuminsensit
bacteria
despit
select
evalu
tellurium
therapeut
agent
realli
progress
significantli
point
time
perhap
owe
perceiv
problem
toxic
mention
sever
occas
deterr
evalu
tellurium
compound
therapeut
potenti
point
particularli
apposit
consider
wide
rang
use
biolog
properti
exhibit
anoth
anion
trichlorido
dioxoethylen
tellur
iv
found
ammonium
salt
molecular
structur
compris
pentacoordin
tellurium
atom
coordin
two
oxygen
atom
deriv
chelat
alkoxid
ligand
three
chlorid
atom
figur
coordin
geometri
base
squar
pyramid
stereochem
activ
lone
pair
anion
report
nontox
potent
immunomodul
display
varieti
potenti
therapeut
applic
attract
attent
term
potenti
anticanc
activ
base
divers
preclin
clinic
studi
anticanc
effect
review
recent
direct
inhibit
antiinflammatori
cytokin
concomit
enhanc
particular
cytokin
level
thought
respons
activ
patient
advanc
cancer
treat
phase
clinic
trial
observ
increas
product
secret
certain
cytokin
result
domin
decreas
respons
respect
effect
might
explain
mechan
sensit
tumor
cell
chemotherapi
main
target
known
lesser
extent
activ
cytokin
upregul
survivin
gene
express
malign
cell
requir
converg
constitut
activ
signal
tumor
feasibl
inhibit
ultim
result
inhibit
subsequ
repress
survivin
support
propos
observ
inhibit
survivin
protein
express
myeloma
cell
compound
speci
bi
r
rtartrato
ditellurium
iv
dinuclear
compound
featur
tetracoordin
tellurium
iv
atom
stereochem
activ
lone
pair
electron
figur
effect
aspart
serin
metalloproteas
select
inact
cystein
proteas
indic
select
protein
reliant
upon
redox
statu
cystein
biolog
activ
characterist
enabl
inhibit
integrin
locat
endotheli
cell
account
antiangiogen
properti
also
note
function
protect
agent
homocystein
toxic
abil
oxid
homocystein
less
toxic
disulfid
homocystin
compound
also
demonstr
potenti
neurogen
diseas
exampl
parkinson
diseas
autoimmun
diseas
induc
mesangi
prolifer
kidney
viral
parasit
diseas
dermat
wide
rang
potenti
therapeut
applic
surpris
tellurium
compound
investig
emphasi
specif
target
relev
biolog
site
cathepsin
b
figur
promin
among
organotellurium
compound
charg
neutral
malaria
target
sever
studi
tellurium
analog
speci
selenium
contain
measur
greater
potenc
selenium
compound
p
falciparum
charg
speci
butyltellanyl
design
target
lowmolecularweight
thioredoxin
reductas
complementari
trial
effect
antimalari
anoth
charg
speci
featur
figur
squarepyramid
tellurium
iv
atom
signific
hyperval
interact
owe
presenc
organo
substitu
contrast
close
relat
figur
trial
antileishmaniasi
potenti
vivo
model
demonstr
activ
flagel
nonflagel
form
parasit
neutral
organotellurium
ii
compound
z
butyltellanyl
methylsulfanyl
ethenyl
benzen
display
potenti
excitotox
agent
owe
antioxid
abil
forego
tellurium
compound
either
oxid
state
coordin
organotellurium
compound
charg
neutral
offer
signific
potenti
drug
develop
densiti
half
water
lithium
li
lightest
metal
known
natur
biolog
function
lithium
salt
commonli
form
li
co
lithicarb
quilonum
eskalith
lithobid
lithon
lithotab
also
li
li
citrat
well
known
psychopharmacolog
agent
lithium
known
influenc
neurotransmitt
receptormedi
signal
signal
transduct
cascad
regul
hormon
circadian
cycl
ion
transport
gene
express
rang
activ
lithium
salt
standard
pharmacolog
treatment
bipolar
disord
year
despit
emerg
drug
lithium
salt
continu
use
firstlin
treatment
acut
mania
use
prophylact
recurr
manic
depress
episod
clinic
lithium
salt
also
use
adjunct
moodstabil
drug
antidepress
antipsychot
order
optim
therapeut
benefit
also
known
lithium
salt
strong
antisuicid
properti
despit
prescrib
clinic
treatment
sever
neurodegen
condit
half
centuri
precis
mechan
actionbiolog
target
lithium
still
subject
debat
consider
evid
indic
lithium
exert
signific
neuroprotectiveneurotroph
properti
variou
insult
base
pharmacolog
gene
manipul
studi
main
mechan
action
lithium
appear
inhibit
glycogen
synthas
induct
brainderiv
neurotroph
factormedi
signal
lead
pathway
enhanc
cell
surviv
alter
variou
downstream
effector
lithium
also
contribut
calcium
homeostasi
inhibit
nmethyldaspart
receptormedi
calcium
influx
suppress
calciumdepend
activ
proapoptot
signal
pathway
lithium
also
implic
recent
identifi
process
tout
novel
mechan
induc
autophagi
inhibit
phosphoinositol
phosphatas
lithium
decreas
inositol
concentr
whatev
precis
mechanismmechan
action
clear
therapeut
dose
lithium
abl
defend
neuron
cell
divers
form
death
insult
lithium
known
mani
year
improv
behavior
trait
cognit
defici
patient
suffer
neurodegen
diseas
includ
stroke
amyotroph
later
sclerosi
fragil
x
syndrom
well
huntington
alzheim
parkinson
diseas
therapeut
util
perhap
surpris
signific
research
develop
explor
new
form
lithium
mode
administr
appar
herein
use
potenti
therapeut
use
maingroup
element
includ
lithium
survey
evid
compound
present
divers
rang
clinic
outcom
certain
type
cancer
treat
arsen
galliumcontain
speci
leishmaniasi
antimoni
compound
gastric
ulcer
bismuth
formul
neurodegen
diseas
lithium
salt
despit
current
applic
acknowledg
precis
molecular
structur
let
alon
mechan
action
often
known
compound
enter
pharmacopoeia
stringent
regul
modern
time
perhap
greater
knowledg
structur
mechan
action
effect
drug
design
clearli
indic
known
crystal
structur
mani
biolog
activ
molecul
describ
herein
supramolecular
aggreg
hyperval
donor
atom
interact
appar
indic
possibl
consist
mode
action
wherebi
metal
center
put
drug
anchor
onto
target
biomolecul
interact
great
potenti
obviou
maingroup
element
compound
therapeut
window
might
avail
element
dismiss
toxic
provid
pharmacolog
benefit
obviou
outstand
exampl
arsen
chang
paradigm
oblig
research
element
neglect
owe
perceiv
problem
toxic
howev
research
reliant
complementari
vivo
studi
includ
quest
discov
biolog
target
mechan
studi
prove
potenti
vitro
studi
often
incomplet
ambigu
full
rang
diseas
tackl
cancer
microbi
diseas
latter
overcom
drug
resist
may
possibl
use
ordinari
maingroup
element
known
biolog
sme
te
te
na
function
inspir
tradit
medicin
ignor
chines
tradit
medicin
inspir
studi
therapeut
arsen
emphasi
molecular
compound
nanoparticl
maingroup
element
cover
signific
extent
present
survey
remain
almost
unchart
frontier
deserv
greater
investig
summari
maingroupelementcontain
speci
deserv
greater
attent
new
therapeut
agent
undoubtedli
discov
road
less
travel
